[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

625.O1.6 Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Novel Targeted Therapies

Program: Oral and Poster Abstracts
Type: Oral
Sunday, December 5, 2010: 4:30 PM-6:00 PM
308 (Orange County Convention Center)
Moderators:
Jeremy S. Abramson, MD, Center for Lymphoma, Massachusetts General Hospital and Weiyun Ai, MD, PhD, Univ of California, San Francisco
4:30 PM
HDAC Class I Inhibition Acetylates a Non-Histone Protein STAT3 by Modulating p300-STAT3-HDAC1 Interaction In Activated B- Cell Like (ABC) Diffuse Large B Cell Lymphoma

Mamta Gupta, Ph.D, Jing Jing Han*, Mary Stenson*, Linda Wellik* and Thomas E. Witzig, MD

Hematology, Mayo Clinic, Rochester, MN

4:45 PM
Potentiation of Bortezomib-Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I-κBα Degradation

Li Jia, PhD, MD1, Ganga Gopinathan2*, Johanna T Sukumar2* and John G. Gribben, MD, DSc2

1Centre for Haemato-Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
2Centre for Medical Oncology, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

5:00 PM
Metabolic Targeted Therapy for Aggressive B-Cell Lymphomas:  Evaluating Glucose Metabolism and the Potential of 187rhenium- Ethylenedicysteine –N-AcetylGlucosamine (187Re-ECG) for Therapy

Lan V Pham, Ph.D1*, Jerry Bryant, M.S.2*, Archito Tamayo, M.S.1*, Richard Mendez, M.S.3*, Edna Chum1*, David Yang, Ph.D3*, David Rollo, MD, Ph.D2* and Richard J. Ford, MD, PhD4

1Hematopathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
2Cell Point, Centennial, CO
3Experimental Diagnostic Imaging, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
4Department of Hematopathology, UT M.D. Anderson Cancer Center, Houston, TX

5:15 PM
The Novel Kinesin Spindle Protein Inhibitor SB-743921 Exhibits Marked Activity In In Vivo and In Vitro In Models of Aggressive Diffuse Large B-Cell Lymphoma

Danielle C Bongero1*, Luca Paoluzzi, MD1*, Enrica Marchi, M.D., Ph.D.2*, Neisa Roberto, PhD3*, Rafael Escandon4*, Ken Wood, PhD4* and Owen A. O'Connor, MD, PhD5

1NYU Cancer Institute, NYU Langone Medical Center, New York, NY
2NYU Cancer Institute, NYU Medical Center, New York, NY
3Columbia University, New York
4Cytokinetics, Inc., San Francisco,, CA
5NYU Clinical Cancer Institute, NYU Langone Medical Center, New York, NY

5:30 PM
Targeting Translation Bypasses Pim Kinase Activity, a Common and Adverse Prognostic Marker In Lymphoma

Jonathan H. Schatz, MD1, Julie Teruya-Feldstein, MD2, Man Jiang3*, Andrew D Zelenetz, MD1 and Hans-Guido Wendel, MD3*

1Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
2Dept. of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
3Cancer Biology and Genetics Program, Sloan-Kettering Institute for Cancer Research, New York, NY

5:45 PM
Targeting Sp1 Transactivation In Waldenstrom’s Macroglobulinemia: a Novel Therapeutic Option

Mariateresa Fulciniti, PhD1*, Samir B. Amin, MBBS1*, Varuna Mohan1*, Guang Yang, MD2*, Puru Nanjappa1*, Pierfrancesco Tassone3*, Rao H Prabhala, Ph.D.4, Li Cheng1*, Kenneth C. Anderson, MD5, Steven P Treon, MD, PhD6 and Nikhil C. Munshi, MD7

1Dana Farber Cancer Institute, Boston, MA
2Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA
3University of Catanzaro, Catanzaro, Italy
4Va Boston Healthcare System, West Roxbury, MA
5Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
6Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
7Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

*signifies non-member of ASH